The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
Open accessAbstract
Because the use of fluconazole prophylaxis had been associated with an increased rate of Candida krusei infections at The John Hopkins Oncology Center, early empiric amphotericin B plus flucytosine were given to febrile neutropenic patients colonized by C. krusei. By this practice, the proportion of fungemias attributable to C. krusei was low (12.5%) in patients receiving fluconazole over a 6-month interval. However, Torulopsis (Candida) glabrata assumed a much higher proportion of fungemias (75%) among patients receiving fluconazole. In vitro susceptibility testing combined with this clinical experience suggests that some T. glabrata isolates are not susceptible to fluconazole and can cause breakthrough infections in patients receiving fluconazole.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Self-citationIncidence of polyene-resistant yeasts recovered from clinical specimens
Dick, J. D., Merz, W. G., & Saral, R. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.18.1.158 · Cited by 242
Self-citationFLUCONAZOLE RESISTANCE IN CANDIDA GLABRATA
Warnock, D. W., Burke, J., Cope, N. J., Johnson, E. M., Fraunhofer, N. A. V., & Williams, E. W. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92919-4 · Cited by 146
Fluconazole andCandida kruseiFungemia
Persons, D. A., Laughlin, M. A., Tanner, D., Perfect, J. R., Gockerman, J. P., & Hathorn, J. W. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251814 · Cited by 98
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956
“This likely reflects, in part, selective pressure because of the extensive use of prophylactic fluconazole in susceptible hosts [32, 33].”
BackgroundEpidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Self-citationPotential Role of Phospholipases in Virulence and Fungal Pathogenesis
Ghannoum, M. A. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.1.122 · Cited by 818
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever
Hughes, W. T., Armstrong, D., Bodey, G. P., Brown, A. E., Edwards, J. E., Feld, R., Pizzo, P., Rolston, K. V. I., Shenep, J. L., & Young, L. S. (1997) · Clinical Infectious Diseases · doi:10.1086/513764 · Cited by 672
Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601
Nosocomial Candidiasis: Emerging Species, Reservoirs, and Modes of Transmission
Pfaller, M. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s89 · Cited by 502
Marr, K. A., Seidel, K., White, T. C., & Bowden, R. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315193 · Cited by 493
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00192-2 · Cited by 424
Winston, D. J., Maziarz, R. T., Chandrasekar, P. H., Lazarus, H. M., Goldman, M., Blumer, J. L., Leitz, G. J., & Territo, M. C. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-9-200305060-00006 · Cited by 389
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
The Ins and Outs of DNA Fingerprinting the Infectious Fungi
Soll, D. R. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.332 · Cited by 346
Hachem, R., Hanna, H., Kontoyiannis, D., Jiang, Y., & Raad, I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 331
Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Pelz, R. K., Hendrix, C. W., Swoboda, S. M., Diener-West, M., Merz, W. G., Hammond, J., & Lipsett, P. A. (2001) · Annals of Surgery · doi:10.1097/00000658-200104000-00010 · Cited by 316
Self-citationAntifungal Resistance in Pathogenic Fungi
Perea, S., & Patterson, T. F. (2002) · Clinical Infectious Diseases · doi:10.1086/344058 · Cited by 289
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Hollis, R. J., Messer, S. A., & Group, F. T. S. P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.1886-1889.1998 · Cited by 281
Rotstein, C., Bow, E. J., Laverdiere, M., Ioannou, S., Carr, D., Moghaddam, N., & The Canadian Fluconazole Prophylaxis Study Group (1999) · Clinical Infectious Diseases · doi:10.1086/515128 · Cited by 265
Pfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Winston, D. J., Pakrasi, A., & Busuttil, R. W. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-10-199911160-00003 · Cited by 261
Phillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Fong, I., Salit, I., Miller, M., Williams, K., Conly, J. M., et al. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01726360 · Cited by 221
Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., & Hajjeh, R. A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00160-6 · Cited by 216
Bodey, G. P., Mardani, M., Hanna, H. A., Boktour, M., Abbas, J., Girgawy, E., Hachem, R. Y., Kontoyiannis, D. P., & Raad, I. I. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01130-5 · Cited by 209
Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial
Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00004 · Cited by 210
“5 (4–171) 9 (4–57) Median previous hospital stay (range), d 11 (5–173) 11 (4–58) Median baseline APACHE II score (range) 22 (9–28) 20 (11–42) Corticosteroids, n (%) 19 (16) 15 (12) Total parenteral nutrition, n (%) 70 (57) 65 (51) Renal insufficiency, n (%)† 70 (57) 65 (51) Colonized with yeast in 1 site, n (%) 28 (23…”
Geber, A., Hitchcock, C. A., Swartz, J. E., Pullen, F. S., Marsden, K. E., Kwon-Chung, K. J., & Bennett, J. E. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2708 · Cited by 203
Breakthrough invasive fungal infections: Who is at risk?
Jenks, J. D., Cornely, O. A., Chen, S. C. ‐., Thompson, G. R., & Hoenigl, M. (2020) · Mycoses · doi:10.1111/myc.13148 · Cited by 191
Winston, D. J., Hathorn, J. W., Schuster, M. G., Schiller, G. J., & Territo, M. C. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00457-x · Cited by 189
Management and outcome of bloodstream infections due to Candida species in England and Wales
Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Johnson, E. M., Perry, J. D., Sullivan, D. J., & Wilson, J. A. (2003) · Journal of Hospital Infection · doi:10.1016/s0195-6701(03)00085-9 · Cited by 187
Andes, D. R., Safdar, N., Baddley, J. W., Alexander, B., Brumble, L., Freifeld, A., Hadley, S., Herwaldt, L., Kauffman, C., Lyon, G. M., et al. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12613 · Cited by 182
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166
Hernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1382-1383.2004 · Cited by 162
Prophylactic antifungal therapy in the intensive care unit
Weinstein, R. A., Rex, J. H., & Sobel, J. D. (2001) · Clinical Infectious Diseases · doi:10.1086/319763 · Cited by 155
Risk factors for albicans and non-albicans candidemia in the intensive care unit*
Chow, J. K., Golan, Y., Ruthazer, R., Karchmer, A. W., Carmeli, Y., Lichtenberg, D. A., Chawla, V., Young, J. A., & Hadley, S. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31816fc4cd · Cited by 154
Antifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153
White, M. H. (1997) · Clinical Infectious Diseases · doi:10.1086/513661 · Cited by 151
Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750
Barchiesi, F., Calabrese, D., Sanglard, D., Falconi Di Francesco, L., Caselli, F., Giannini, D., Giacometti, A., Gavaudan, S., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1578-1584.2000 · Cited by 145
“Second, the introduction of particular surgical devices, prostheses, and indwelling intravenous catheters has increased the risk of yeast infections due to Candida species which originate mainly from the environment (37, 38).”
BackgroundTrends in Antifungal Use and Epidemiology of Nosocomial Yeast Infections in a University Hospital
Berrouane, Y. F., Herwaldt, L. A., & Pfaller, M. A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.531-537.1999 · Cited by 136
Viscoli, C., Castagnola, E., Van Lint, M. T., Moroni, C., Garaventa, A., Rossi, M. R., Fanci, R., Menichetti, F., Caselli, D., Giacchino, M., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00619-2 · Cited by 122
In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine
Mitsuyama, J., Nomura, N., Hashimoto, K., Yamada, E., Nishikawa, H., Kaeriyama, M., Kimura, A., Todo, Y., & Narita, H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01159-07 · Cited by 111
“However, there is a great concern because of the increased prevalence of Candida glabrata isolates exhibiting reduced susceptibility to triazole antifungals and of Candida krusei, which has developed an intrinsic resistance to fluconazole and itraconazole due to the empirical use of triazole-based drugs, especially in…”
BackgroundMalik, I. A., Moid, I., Aziz, Z., Khan, S., & Suleman, M. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00326-x · Cited by 106
Safdar, A., van Rhee, F., Henslee-Downey, J., Singhal, S., & Mehta, J. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703252 · Cited by 93
Transcriptional profiling of azole-resistant Candida parapsilosis strains
Silva, A. P., Miranda, I. M., Guida, A., Synnott, J., Rocha, R., Silva, R., Amorim, A., Pina-Vaz, C., Butler, G., & Rodrigues, A. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01127-10 · Cited by 86
Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata
Blot, S., Vandewoude, K., Hoste, E., Poelaert, J., & Colardyn, F. (2001) · Journal of Hospital Infection · doi:10.1053/jhin.2000.0918 · Cited by 73
Risk factors for death among cancer patients with fungemia
Nucci, M., Silveira, M. I., Spector, N., Silveira, F., Velasco, E., Akiti, T., Barreiros, G., Derossi, A., Colombo, A. L., & Pulcheri, W. (1998) · Clinical Infectious Diseases · doi:10.1086/514609 · Cited by 69
Zhang, L., Xiao, M., Watts, M. R., Wang, H., Fan, X., Kong, F., & Xu, Y.-C. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1086-6 · Cited by 62
Advances in Candida detection platforms for clinical and point-of-care applications
Safavieh, M., Coarsey, C., Esiobu, N., Memic, A., Vyas, J. M., Shafiee, H., & Asghar, W. (2017) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2016.1167667 · Cited by 57
T., B., W., F., H., B., N., B., K.-H., D., M., H., D., H., U., J., G., J.-N., M., K., et al. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0730-4 · Cited by 53
Vazquez, J. A., Sobel, J. D., Peng, G., Steele‐Moore, L., Schuman, P., Holloway, W., Neaton, J. D., & (CPCRA), T. T. B. C. P. F. C. R. I. A. (1999) · Clinical Infectious Diseases · doi:10.1086/514746 · Cited by 51
Alp, S., Arikan‐Akdagli, S., Gulmez, D., Ascioglu, S., Uzun, O., & Akova, M. (2015) · Mycoses · doi:10.1111/myc.12349 · Cited by 32
Orasch, C., Mertz, D., Garbino, J., van Delden, C., Emonet, S., Schrenzel, J., Zimmerli, S., Damonti, L., Mühlethaler, K., Imhof, A., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2017.12.018 · Cited by 19
Metadata
- Authors
- Wingard, J. R., Merz, W. G., Rinaldi, M. G., Miller, C. B., Karp, J. E., & Saral, R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1993-09
- Volume
- 37
- Issue
- 9
- Pages
- 1847-1849
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2108439465
- Cited by
- 340
- References
- 5
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.